Simulations Plus (SLP) Projected to Post Quarterly Earnings on Wednesday

Simulations Plus (NASDAQ:SLP) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, October 22nd. Analysts expect the company to announce earnings of $0.07 per share and revenue of $16.4740 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 23, 2025 at 4:00 PM ET.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings data on Monday, July 14th. The technology company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.19. The company had revenue of $20.36 million for the quarter, compared to analyst estimates of $22.83 million. Simulations Plus had a positive return on equity of 11.62% and a negative net margin of 78.63%.The firm’s revenue for the quarter was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.27 EPS. On average, analysts expect Simulations Plus to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Simulations Plus Price Performance

Shares of NASDAQ:SLP opened at $15.26 on Wednesday. The business’s 50 day simple moving average is $14.71 and its 200-day simple moving average is $20.96. The firm has a market capitalization of $307.18 million, a price-to-earnings ratio of -4.84 and a beta of 0.99. Simulations Plus has a 12 month low of $12.39 and a 12 month high of $37.67.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SLP shares. Cowen started coverage on Simulations Plus in a research note on Tuesday, September 30th. They set a “hold” rating on the stock. Stephens decreased their price target on Simulations Plus from $28.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 15th. TD Cowen started coverage on Simulations Plus in a research note on Tuesday, September 30th. They set a “hold” rating and a $16.00 price target on the stock. BTIG Research decreased their price target on Simulations Plus from $41.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, July 7th. Finally, KeyCorp lowered Simulations Plus from an “overweight” rating to a “sector weight” rating in a research note on Tuesday, July 15th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Simulations Plus presently has a consensus rating of “Hold” and an average target price of $24.40.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SLP. First Light Asset Management LLC acquired a new position in Simulations Plus in the 2nd quarter valued at $6,232,000. Ameriprise Financial Inc. raised its holdings in Simulations Plus by 25.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company’s stock valued at $15,277,000 after acquiring an additional 176,747 shares during the last quarter. Marshall Wace LLP raised its holdings in Simulations Plus by 435.9% in the 2nd quarter. Marshall Wace LLP now owns 133,278 shares of the technology company’s stock valued at $2,326,000 after acquiring an additional 108,407 shares during the last quarter. Federated Hermes Inc. raised its holdings in Simulations Plus by 493.4% in the 2nd quarter. Federated Hermes Inc. now owns 66,459 shares of the technology company’s stock valued at $1,160,000 after acquiring an additional 55,259 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in Simulations Plus by 26.6% in the 1st quarter. Royal Bank of Canada now owns 114,885 shares of the technology company’s stock valued at $2,817,000 after acquiring an additional 24,132 shares during the last quarter. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.